June 9, 2023

Oxford Nanopore Technologies and Geneyx Announce the First Scalable Software Solution to Advance the Future Clinical Use of Nanopore Sequencing

Business Wire

The new platform is designed to enable the end-to-end analysis and clinical reporting of nanopore sequencing, empowering clinical labs, researchers and other users with an advanced, “one-click” solution

June 09, 2023 02:16 PM Eastern Daylight Time

OXFORD, England–(BUSINESS WIRE)–Oxford Nanopore Technologies plc (Oxford Nanopore), the company delivering a new generation of nanopore-based molecular sensing technology, and Geneyx, an AI platform for human genetic analysis and interpretation, are aiming to team up to develop the first scalable software solution for the end-to-end analysis and clinical reporting of nanopore sequencing data. The advanced platform will seamlessly empower clinical centres including hospitals, genetic labs and researchers with human whole-genome sequencing data and analysis.

The new software platform, which is anticipated to be commercially available following the completion of a pilot phase, is intended to advance the future clinical use of nanopore sequencing and will be designed to load, visualise and annotate nanopore sequencing data. Once available, it will be of immediate use in newborn screening and the research and characterisation of rare and undiagnosed diseases, providing “one-click” analysis of whole human sequencing data, including actionable genetic variants.

The collaboration will combine Geneyx’s data analysis capabilities with Oxford Nanopore’s human-variation workflow and secure data transfer. The platform will seamlessly integrate with EPI2ME™, Oxford Nanopore’s data analysis solution, which will perform the secondary sequence analysis. The results will then be pushed to the Geneyx cloud and on-site capability, where precise annotation and classification of the variants will be performed, providing a further layer of simplified bioinformatics designed for future clinical use.

The partnership will kick off with pilot projects to evaluate this software solution within third-party sites. The Geneyx solution is currently used by 4,000 active users in 36 countries worldwide.

Gordon Sanghera, CEO, Oxford Nanopore Technologies, commented:

“We are excited to collaborate with Geneyx to develop an end-to-end analysis tool for the clinical reporting of nanopore sequencing data. Through this seamless integration, customers will benefit from the combined power of nanopore sequencing with Geneyx’s AI-powered analysis for an added layers of insight to support critical workflows such as newborn screening and research into rare disease.”

David Yizhar, CEO, Geneyx commented:

“This collaboration combines Geneyx’s analysis expertise with Oxford Nanopore Technologies groundbreaking sequencing technology. This will enable us to deliver robust and accurate genetic insights to healthcare providers, including a comprehensive genomic solution for Long-Read whole genome sequencing analysis. Together, we will elevate research and diagnostics, empowering patients and researchers seeking answers.”

About Oxford Nanopore Technologies

Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. www.nanoporetech.com

For more Geneyx News click here

Additional Articles

News

Geneyx Among the World's Best Digital Health Companies in 2024

May 15, 2024

Geneyx Among the World’s Best Digital Health Companies in 2024

Newsweek

This acknowledgment highlights Geneyx's significant contributions to the rapidly expanding digital health sector.

Children's Mercy Kansas City and Geneyx Inc. Announce Collaboration to Advance Genomic Research and Analysis

March 13, 2024

Children’s Mercy Kansas City and Geneyx Inc. Announce Collaboration to Advance Genomic Research and Analysis

PR Newswire

Children's Mercy Kansas City, one of the leading independent pediatric health organizations, and Geneyx Inc. are pleased to announce a collaboration aimed at advancing genomic research and analysis.

PacBio Geneyx Press Release

November 1, 2023

PacBio Enables Rare and Inherited Disease Research by Adding Tertiary Analysis Partner Geneyx to PacBio Compatible

PacBio

Partnerships maximize value of HiFi data and complete the full end-to-end workflow for PacBio customers.

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

July 26, 2023

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

Geneyx

Geneyx and Ocean Genomics develop a multiomic software method, combining DNA and RNA.

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

July 26, 2023

BIRD Foundation invests $8 million in 9 new projects

James Spiro

Geneyx and Ocean Genomics will develop a multiomic software method, combining DNA and RNA.

Bioinformatics Startup Geneyx Builds Business on Whole-Genome, Long-Read Sequencing Analysis

June 21, 2023

Bioinformatics Startup Geneyx Builds Business on Whole-Genome, Long-Read Sequencing Analysis

Neil Versel

This month's announcement that Oxford Nanopore Technologies would integrate its Epi2Me cloud-based analysis platform with Geneyx's software to automate analysis and clinical reporting of long-read sequencing data

Previous
Next
Geneyx Among the World's Best Digital Health Companies in 2024

May 15, 2024

Geneyx Among the World’s Best Digital Health Companies in 2024

Newsweek

This acknowledgment highlights Geneyx's significant contributions to the rapidly expanding digital health sector.

Children's Mercy Kansas City and Geneyx Inc. Announce Collaboration to Advance Genomic Research and Analysis

March 13, 2024

Children’s Mercy Kansas City and Geneyx Inc. Announce Collaboration to Advance Genomic Research and Analysis

PR Newswire

Children's Mercy Kansas City, one of the leading independent pediatric health organizations, and Geneyx Inc. are pleased to announce a collaboration aimed at advancing genomic research and analysis.

PacBio Geneyx Press Release

November 1, 2023

PacBio Enables Rare and Inherited Disease Research by Adding Tertiary Analysis Partner Geneyx to PacBio Compatible

PacBio

Partnerships maximize value of HiFi data and complete the full end-to-end workflow for PacBio customers.

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

July 26, 2023

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

Geneyx

Geneyx and Ocean Genomics develop a multiomic software method, combining DNA and RNA.

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

July 26, 2023

BIRD Foundation invests $8 million in 9 new projects

James Spiro

Geneyx and Ocean Genomics will develop a multiomic software method, combining DNA and RNA.

Bioinformatics Startup Geneyx Builds Business on Whole-Genome, Long-Read Sequencing Analysis

June 21, 2023

Bioinformatics Startup Geneyx Builds Business on Whole-Genome, Long-Read Sequencing Analysis

Neil Versel

This month's announcement that Oxford Nanopore Technologies would integrate its Epi2Me cloud-based analysis platform with Geneyx's software to automate analysis and clinical reporting of long-read sequencing data

+

Selected Videos

Geneyx Analysis Version 5.12 Release

Previous
Next

Schedule Demo

Contact us to set a live demo


Contact Us

Whether you have general questions about our solutions or would like to schedule a demo or to suggest collaboration – our team is on hand for you.